Lv3
228 积分 2024-03-05 加入
Efgartigimod in Very-Late-Onset Generalized Myasthenia Gravis: A Real-World Study on Effectiveness and Safety
5个月前
已完结
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience
5个月前
已完结
Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial
5个月前
已完结
Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study
5个月前
已完结
A Prospective Clinical Trial of Efgartigimod for New-Onset Generalized Myasthenia Gravis
5个月前
已完结
Getting specific: targeting Fc receptors in myasthenia gravis
7个月前
已完结
CD19xCD3 T-cell engager blinatumomab effective in refractory generalized myasthenic syndromes
10个月前
已完结
TRPM7 contributes to pyroptosis and its involvement in status epilepticus
10个月前
已完结
Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer’s disease
11个月前
已完结
PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration
11个月前
已完结
皖公网安备34019202002308
